Want to see HK:2509 full AI Analyst Report?
Qyuns Therapeutics Co., Ltd. Class H (2509) Ratios
Qyuns Therapeutics Co., Ltd. Class H Ratios
HK:2509's free cash flow for Q2 2026 was $9.20M. For the 2026 fiscal year, HK:2509's free cash flow was decreased by $-4.95M and operating cash flow was $14.14M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.22 | 1.43 | 1.66 | 5.84 | 7.61 |
| Quick Ratio | 2.14 | 1.43 | 1.65 | 5.84 | 7.61 |
| Cash Ratio | 1.91 | 0.84 | 0.86 | 1.96 | 3.13 |
| Solvency Ratio | 0.37 | -0.40 | -0.96 | -0.64 | -0.87 |
| Operating Cash Flow Ratio | 0.79 | -0.43 | -1.19 | -2.25 | -1.85 |
| Short-Term Operating Cash Flow Coverage | 2.23 | -0.88 | -2.51 | -4.55 | -10.60 |
| Net Current Asset Value | $ 195.52M | $ -146.10M | $ -76.30M | $ 294.45M | $ 203.82M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.54 | 0.43 | 0.25 | 0.22 |
| Debt-to-Equity Ratio | 0.84 | 2.30 | 1.07 | 0.46 | 0.43 |
| Debt-to-Capital Ratio | 0.46 | 0.70 | 0.52 | 0.32 | 0.30 |
| Long-Term Debt-to-Capital Ratio | 0.37 | 0.58 | 0.41 | 0.27 | 0.29 |
| Financial Leverage Ratio | 2.31 | 4.30 | 2.45 | 1.81 | 1.95 |
| Debt Service Coverage Ratio | 1.75 | -1.33 | -3.55 | -3.73 | -4.76 |
| Interest Coverage Ratio | 14.81 | -13.95 | -29.99 | -15.71 | -9.45 |
| Debt to Market Cap | 0.15 | 0.35 | 0.08 | 0.06 | 0.07 |
| Interest Debt Per Share | 2.69 | 2.51 | 1.76 | 1.41 | 1.39 |
| Net Debt to EBITDA | -1.09 | -0.54 | -0.27 | -0.19 | -0.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 84.55% | 58.06% | 100.00% | -267.57% | -44.77% |
| EBIT Margin | 40.68% | -215.56% | -3486.18% | -3354.95% | -840.05% |
| EBITDA Margin | 44.76% | -196.37% | -3281.95% | -3058.45% | -729.06% |
| Operating Profit Margin | 40.68% | -205.53% | -3420.19% | -3039.63% | -789.84% |
| Pretax Profit Margin | 38.09% | -220.26% | -3534.22% | -3233.09% | -1997.96% |
| Net Profit Margin | 38.97% | -211.33% | -3442.13% | -3086.22% | -1925.33% |
| Continuous Operations Profit Margin | 38.08% | -220.22% | -3533.73% | -3232.33% | -1997.62% |
| Net Income Per EBT | 102.30% | 95.94% | 97.39% | 95.46% | 96.36% |
| EBT Per EBIT | 93.64% | 107.17% | 103.33% | 106.36% | 252.96% |
| Return on Assets (ROA) | 19.13% | -34.11% | -63.82% | -25.66% | -31.48% |
| Return on Equity (ROE) | 44.12% | -146.55% | -156.45% | -46.47% | -61.32% |
| Return on Capital Employed (ROCE) | 29.15% | -58.94% | -92.77% | -28.24% | -13.81% |
| Return on Invested Capital (ROIC) | 25.02% | -42.61% | -75.88% | -26.64% | -15.44% |
| Return on Tangible Assets | 19.40% | -34.23% | -64.01% | -26.19% | -32.00% |
| Earnings Yield | 8.12% | -22.06% | -11.12% | -6.21% | -9.28% |
| Efficiency Ratios | |||||
| Receivables Turnover | 39.54 | 6.04 | 40.52 | 14.60 | 60.31 |
| Payables Turnover | 1.25 | 0.60 | 0.00 | 1.86 | 2.45 |
| Inventory Turnover | 3.19 | 19.96 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.54 | 0.48 | 0.04 | 0.02 | 0.04 |
| Asset Turnover | 0.49 | 0.16 | 0.02 | 0.01 | 0.02 |
| Working Capital Turnover Ratio | 1.97 | 0.90 | 0.04 | 0.02 | 0.00 |
| Cash Conversion Cycle | -167.19 | -529.01 | 9.01 | -171.67 | -142.72 |
| Days of Sales Outstanding | 9.23 | 60.41 | 9.01 | 25.01 | 6.05 |
| Days of Inventory Outstanding | 114.46 | 18.28 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 290.88 | 607.70 | 0.00 | 196.68 | 148.77 |
| Operating Cycle | 123.69 | 78.69 | 9.01 | 25.01 | 6.05 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.79 | -0.85 | -1.46 | -1.24 | -0.71 |
| Free Cash Flow Per Share | 1.75 | -0.85 | -1.50 | -1.36 | -1.03 |
| Dividend Paid and CapEx Coverage Ratio | 52.46 | -152.03 | -37.84 | -10.40 | -2.22 |
| Capital Expenditure Coverage Ratio | 52.46 | -152.03 | -37.84 | -10.40 | -2.22 |
| Operating Cash Flow Coverage Ratio | 0.69 | -0.35 | -0.87 | -0.93 | -0.54 |
| Operating Cash Flow to Sales Ratio | 0.51 | -1.17 | -20.38 | -28.49 | -7.38 |
| Free Cash Flow Yield | 10.39% | -12.23% | -6.76% | -6.28% | -5.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 12.31 | -4.53 | -8.99 | -16.11 | -10.78 |
| Price-to-Sales (P/S) Ratio | 4.80 | 9.58 | 309.52 | 497.22 | 207.55 |
| Price-to-Book (P/B) Ratio | 5.43 | 6.64 | 14.07 | 7.49 | 6.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.62 | -8.17 | -14.79 | -15.92 | -19.38 |
| Price-to-Operating Cash Flow Ratio | 9.44 | -8.17 | -15.18 | -17.46 | -28.11 |
| Price-to-Earnings Growth (PEG) Ratio | -0.06 | 0.12 | -0.15 | 4.35 | 0.00 |
| Enterprise Value Multiple | 9.64 | -5.41 | -9.70 | -16.45 | -28.62 |
| Enterprise Value | 3.39B | 1.69B | 4.70B | 4.86B | 4.45B |
| EV to EBITDA | 9.64 | -5.41 | -9.70 | -16.45 | -28.62 |
| EV to Sales | 4.31 | 10.63 | 318.32 | 503.02 | 208.65 |
| EV to Free Cash Flow | 8.65 | -9.07 | -15.21 | -16.11 | -19.48 |
| EV to Operating Cash Flow | 8.48 | -9.07 | -15.62 | -17.66 | -28.26 |
| Tangible Book Value Per Share | 2.94 | 0.99 | 1.45 | 3.24 | 3.78 |
| Shareholders’ Equity Per Share | 3.10 | 1.04 | 1.58 | 2.89 | 3.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 3.51 | 0.72 | 0.07 | 0.04 | 0.10 |
| Net Income Per Share | 1.37 | -1.53 | -2.47 | -1.34 | -1.85 |
| Tax Burden | 1.02 | 0.96 | 0.97 | 0.95 | 0.96 |
| Interest Burden | 0.94 | 1.02 | 1.01 | 0.96 | 2.38 |
| Research & Development to Revenue | 0.30 | 2.11 | 24.70 | 28.02 | 7.11 |
| SG&A to Revenue | 0.17 | 0.74 | 11.16 | 7.93 | 1.12 |
| Stock-Based Compensation to Revenue | 0.06 | 0.48 | 8.90 | 4.30 | 0.55 |
| Income Quality | 1.30 | 0.55 | 0.58 | 0.88 | 0.44 |
Currency in CNY